Development of forced degradation and stability indicating studies of drugs-A review
- PMID: 29403878
- PMCID: PMC5761119
- DOI: 10.1016/j.jpha.2013.09.003
Development of forced degradation and stability indicating studies of drugs-A review
Abstract
Forced degradation is a degradation of new drug substance and drug product at conditions more severe than accelerated conditions. It is required to demonstrate specificity of stability indicating methods and also provides an insight into degradation pathways and degradation products of the drug substance and helps in elucidation of the structure of the degradation products. Forced degradation studies show the chemical behavior of the molecule which in turn helps in the development of formulation and package. In addition, the regulatory guidance is very general and does not explain about the performance of forced degradation studies. Thus, this review discusses the current trends in performance of forced degradation studies by providing a strategy for conducting studies on degradation mechanisms and also describes the analytical methods helpful for development of stability indicating method.
Keywords: Degradation conditions; Degradation product; Forced degradation; Stability indicating method; Stress testing.
Figures
Similar articles
-
Pharmaceutical Forced Degradation (Stress Testing) Endpoints: A Scientific Rationale and Industry Perspective.J Pharm Sci. 2023 Dec;112(12):2948-2964. doi: 10.1016/j.xphs.2023.09.003. Epub 2023 Sep 9. J Pharm Sci. 2023. PMID: 37690775 Review.
-
Assessing the Relevance of Solution Phase Stress Testing of Solid Dosage Form Drug Products: A Cross-Industry Benchmarking Study.J Pharm Sci. 2022 Feb;111(2):298-305. doi: 10.1016/j.xphs.2021.06.012. Epub 2021 Jun 7. J Pharm Sci. 2022. PMID: 34111446
-
Forced degradation studies of biopharmaceuticals: Selection of stress conditions.Eur J Pharm Biopharm. 2016 Jan;98:26-46. doi: 10.1016/j.ejpb.2015.10.016. Epub 2015 Nov 2. Eur J Pharm Biopharm. 2016. PMID: 26542454 Review.
-
Stability-indicating assay method for determination of actarit, its process related impurities and degradation products: Insight into stability profile and degradation pathways☆.J Pharm Anal. 2014 Dec;4(6):374-383. doi: 10.1016/j.jpha.2014.01.002. Epub 2014 Jan 25. J Pharm Anal. 2014. PMID: 29403903 Free PMC article.
-
Current regulatory requirements and practical approaches for stability analysis of pharmaceutical products: A comprehensive review.Int J Pharm. 2018 May 30;543(1-2):328-344. doi: 10.1016/j.ijpharm.2018.04.007. Epub 2018 Apr 7. Int J Pharm. 2018. PMID: 29635054 Review.
Cited by
-
Photodegradation of Rituximab and Critical Evaluation of Its Sensibility to Electromagnetic Radiation.AAPS PharmSciTech. 2022 Sep 29;23(7):271. doi: 10.1208/s12249-022-02412-8. AAPS PharmSciTech. 2022. PMID: 36175743
-
Long-term stability of gentamicin sulfate-ethylenediaminetetraacetic acid disodium salt (EDTA-Na2) solution for catheter locks.J Pharm Anal. 2018 Dec;8(6):386-393. doi: 10.1016/j.jpha.2017.09.004. Epub 2017 Sep 25. J Pharm Anal. 2018. PMID: 30595945 Free PMC article.
-
Stability of mixtures of ondansetron and haloperidol stored in infusors at different temperatures.Eur J Hosp Pharm. 2018 Oct;25(e2):e134-e138. doi: 10.1136/ejhpharm-2017-001412. Epub 2018 Jan 27. Eur J Hosp Pharm. 2018. PMID: 31157084 Free PMC article.
-
An experimental approach probing the conformational transitions and energy landscape of antibodies: a glimmer of hope for reviving lost therapeutic candidates using ionic liquid.Chem Sci. 2021 Jun 22;12(27):9528-9545. doi: 10.1039/d1sc02520a. eCollection 2021 Jul 14. Chem Sci. 2021. PMID: 34349928 Free PMC article.
-
Forced degradation of recombinant monoclonal antibodies: A practical guide.MAbs. 2017 Nov/Dec;9(8):1217-1230. doi: 10.1080/19420862.2017.1368602. Epub 2017 Aug 30. MAbs. 2017. PMID: 28853987 Free PMC article. Review.
References
-
- ICH guidelines, Q1A (R2): Stability Testing of New Drug Substances and Products (revision 2), International Conference on Harmonization. Available from: 〈http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm128204...., 2003.
-
- Reynolds D.W., Facchine K.L., Mullaney J.F. Available guidance and best practices for conducting forced degradation studies. Pharm. Technol. 2002;26(2):48–56.
-
- Brummer H. How to approach a forced degradation study. Life Sci. Technol. Bull. 2011;31:1–4.
-
- FDA Guidance for Industry, INDs for Phase II and III Studies—Chemistry, Manufacturing, and Controls Information, Food and Drug Administration. Available from: 〈http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformat..., 2003.
-
- FDA Guidance for Industry, INDs for Phase 2 and 3 Studies of Drugs, Including Specified Therapeutic Biotechnology-Derived Products, Draft Guidance, Food and Drug Administration. Available from: 〈http://www.fda.gov/ohrms/dockets/98fr/990674gd.pdf〉, 1999.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources